REGN at a glance
Regeneron Pharmaceuticals (REGN, SEC CIK 872589) filed its latest 10-K annual report on February 4, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on October 6, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Regeneron Pharmaceuticals (REGN) reported revenue of $14.3 billion (up 1.0% from FY2024) and net income of $4.5 billion. Diluted EPS was $41.48.
- As of June 30, 2026, 50 institutional investment managers tracked by SignalX reported holding Regeneron Pharmaceuticals (REGN) shares worth $28.9 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by McCourt Marion on September 3, 2026 of 1,131 shares at $857.39 per share.
- Regeneron Pharmaceuticals reported 3 positions worth $177.2 million in its 13F-HR for Q2 2026, filed August 7, 2026. Its largest holdings were Parabilis Medicines, Inc. (PBLS) at 64.4%, Intellia Therapeutics, Inc. (NTLA) at 35.4% and Adicet Bio, Inc. (ACET) at 0.3%.
- In the last 90 days, REGN insiders reported 0 open-market purchases ($0) and 5 open-market sales ($3.3M) on Form 4, a net sale of $3.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $14.3B
- +1.0% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$3.3M
- 13F holders
- 50 funds
- $28.9B · +4 vs prior quarter
- Latest 8-K
- Sep 30, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- Lease financing $720M matures March 2027, full payment due unless extended with lender consent
- Exposure to SOFR-based variable interest rate plus margin tied to debt rating and leverage ratio
- Liabilities for unrecognized tax benefits $1.578B as of December 31, 2025, with high uncertainty in settlement timing
- Ongoing R&D and commercialization costs depend on trial outcomes, regulatory approvals, and market potential
- Contingent payments from collaboration agreements include milestone and royalty payments with unpredictable timing
Management Discussion & Analysis
- Investment portfolio equity securities decreased to $515.8M (Dec 31, 2025) from $1.307B (Dec 31, 2024)
- Foreign exchange risk growing due to international sales and operations; foreign currency hedging strategies considered
Business Overview
- Core business model: Development, manufacturing, and commercialization of innovative biologic drugs and drug-delivery devices with regulatory approval focus
- New emphasis on expanding internal manufacturing capacity and establishing fill/finish capabilities amid production constraints and pandemic-related impacts
- Strategic reliance increased on collaborators and contract manufacturers for bulk production and complex device supply chain management
- Manufacturing capacity limited to facilities in Rensselaer, NY and Limerick, Ireland; investing in expansion and new fill/finish facility undergoing process validation
- Noteworthy risk: Loss of U.S. market exclusivity for EYLEA as biosimilars launched May 2024, impacting patent protection and revenue outlook
AI summary of the REGN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $4,290.7M, up 16.7% YoY from $3,675.6M
- Net income $1,296.9M vs $1,391.6M YoY, diluted EPS $12.23 vs $12.81
- Dupixent sales $5,998.2M, up 38%; EYLEA HD sales $962.6M, up 52%
- EYLEA sales $712.4M, down 52%; combined EYLEA HD and EYLEA sales $1,675.0M, down 21%
- Near-term milestones include FDA decisions for EYLEA HD pre-filled syringe and gMG NDA in November 2026
Risk Factors
- EYLEA U.S. sales decline 41% for six months, reflecting biosimilar competition after exclusivity expired in May 2024
- Dupixent collaboration revenue 48% of total revenue, increasing dependence on Sanofi commercialization
- Pending EYLEA intellectual-property proceedings could affect commercialization and product revenue
- Government healthcare pricing measures could reduce reimbursement, coverage, and product pricing
- EYLEA HD and EYLEA U.S. sales represented 25% of total revenue, creating product concentration risk
AI summary of the REGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- One-time 10-year PSU awards replace CEO and CSO annual equity through 2036, requiring continued service through December 31, 2035
- Maximum awards capped at 2,700,000 PSUs for CEO and 2,900,000 for CSO, with mandatory holding through February 2036
Item EX-99.1: Item EX-99.1
- 10-year PSUs tie executive payouts to pipeline execution, FDA approvals, and New Product Annual Revenues through 2035
- Revenue hurdles: $10B for 250,000 PSUs, $18B for 900,000, and $30B for 1,800,000
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial and operating results announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive earnings details
Item EX-99.1: Item EX-99.1
- Q2 revenue $4.291B, up 17%; non-GAAP EPS $14.29, up 11%, signaling broad commercial momentum
- Dupixent collaboration sales reached $6.0B globally; Sanofi collaboration revenue rose 51% to $2.174B
AI summaries of REGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for REGN
Don't miss the next REGN filing
- Alerts as it files. A push when REGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut REGN, by share count.
- Ask anything. An AI agent that reads every REGN filing and answers with sources.
REGN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| McCourt Marion | Sell | Sep 3, 2026 | 1,131 | $857.39 |
| Guarini Kathryn | M | Sep 2, 2026 | 400 | - |
| Guarini Kathryn | Sell | Sep 2, 2026 | 400 | $850.00 |
| McCourt Marion | Sell | Sep 2, 2026 | 1,215 | $850.00 |
| Guarini Kathryn | M | Sep 2, 2026 | 400 | $719.37 |
| LAROSA JOSEPH J | F | Aug 19, 2026 | 9,019 | $830.15 |
| LAROSA JOSEPH J | M | Aug 19, 2026 | 12,282 | - |
| LAROSA JOSEPH J | M | Aug 19, 2026 | 12,282 | $381.92 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $13.1B | $14.2B | $14.3B |
| Operating Income | $4.0B | $4.0B | $3.6B |
| Net Income | - | $4.4B | $4.5B |
| Op. Margin | 30.9% | 28.1% | 24.9% |
| Net Margin | - | 31.1% | 31.4% |
| Balance Sheet | |||
| Total Assets | $33.1B | $37.8B | $40.6B |
| Equity | $26.0B | $29.4B | $31.3B |
| ROE | - | 15.0% | 14.4% |
| Per Share | |||
| EPS | $34.77 | $38.34 | $41.48 |
| Cash Flow | |||
| Operating CF | $4.6B | $4.4B | $5.0B |
Source: XBRL data in Regeneron Pharmaceuticals (REGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate REGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 50 | $28.86B |
| Q1 2026 | 46 | $35.57B |
| Q4 2025 | 44 | $34.42B |
| Q3 2025 | 45 | $27.01B |
| Q2 2025 | 44 | $23.76B |
| Q1 2025 | 43 | $25.06B |
| Q4 2024 | 37 | $21.65B |
| Q3 2024 | 37 | $13.65B |
- Vanguard Portfolio Management LLC+1.45M (+85%)
- State Street Corp+170.2K (+4%)
- BlackRock+165.8K (+2%)
- Citigroup+161.9K (+88%)
- Millennium Management+102.4K (+163%)
- FMR LLC (Fidelity)−686.2K (-45%)
- T. Rowe Price Group−647.8K (-30%)
- JPMorgan Chase & Co−537.6K (-12%)
- Two Sigma Investments−156.1K (-19%)
- Goldman Sachs Group−137.4K (-11%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 346 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
Regeneron Pharmaceuticals top 13F holdings, Q2 2026
Largest reported positions by market value, from the 13F-HR filed Aug 7, 2026
| # | Company | Weight | Value | Shares | vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | Parabilis Medicines, Inc.PBLS | 64.35% | $114.0M | 4,166,666 | New |
| 2 | Intellia Therapeutics, Inc.NTLA | 35.35% | $62.7M | 3,702,995 | Held |
| 3 | Adicet Bio, Inc.ACET | 0.29% | $523K | 60,511 | Held |
Source: Regeneron Pharmaceuticals 13F-HR on SEC EDGAR. Long equity positions only (put and call options excluded); weights are shares of the reported 13F portfolio, not total assets. How 13F filings work
Regeneron Pharmaceuticals biggest buys and sells, Q2 2026
Largest estimated position changes versus Q1 2026
| Company | Move | Est. flow | Shares now | Weight now |
|---|---|---|---|---|
| Parabilis Medicines, Inc.PBLS | New | +$114.0M | 4,166,666 | 64.35% |
Estimated flow = change in share count × quarter-end price (1 new, 0 added, 0 trimmed, 0 sold out). 13F reports show holdings on the last day of the quarter, not the trade dates.
REGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 6, 2026 | - | - | - |
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 13F-HR | Aug 7, 2026 | Jun 30, 2026 | - | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 7, 2026 | - | - | - |
| 8-K | Jul 6, 2026 | - | Analysis | - |
| 8-K | Jun 17, 2026 | - | Analysis | - |
| 13F-HR | May 8, 2026 | Mar 31, 2026 | - | |
| 4 | May 4, 2026 | - | - | - |
| SC 13G | Apr 30, 2026 | - | - | |
| 8-K | Apr 29, 2026 | - | Analysis | - |
| 10-Q | Apr 29, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 8, 2026 | - | Analysis | - |
| 4 | Apr 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Feb 11, 2026 | - | - | |
| 4 | Feb 11, 2026 | - | - | |
| 13F-HR | Feb 6, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
REGN SEC filings: frequently asked questions
Are REGN insiders buying or selling?
In the last 90 days, Regeneron Pharmaceuticals (REGN) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $3.3 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold REGN stock?
As of June 30, 2026, the largest Regeneron Pharmaceuticals (REGN) holders among the 13F filers tracked by SignalX were BlackRock ($5.7 billion), Vanguard Capital Management LLC ($4.1 billion), State Street Corp ($3.0 billion), Invesco Ltd ($2.5 billion), JPMorgan Chase & Co ($2.4 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was REGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Regeneron Pharmaceuticals (REGN) reported revenue of $14.3 billion (up 1.0% from FY2024) and net income of $4.5 billion. Diluted EPS was $41.48. The figures come from the XBRL data in the 10-K.
What are the main risks in REGN's latest 10-K?
In the 10-K filed February 4, 2026, Regeneron Pharmaceuticals (REGN) flagged: Lease financing $720M matures March 2027, full payment due unless extended with lender consent. Exposure to SOFR-based variable interest rate plus margin tied to debt rating and leverage ratio. (AI summary of the Risk Factors section.)
What did REGN report in its latest 8-K?
Regeneron Pharmaceuticals (REGN) filed an 8-K on September 30, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). One-time 10-year PSU awards replace CEO and CSO annual equity through 2036, requiring continued service through December 31, 2035.
What stocks does Regeneron Pharmaceuticals own?
In its 13F-HR for Q2 2026 (filed August 7, 2026), Regeneron Pharmaceuticals reported 3 positions worth $177.2 million. The largest were Parabilis Medicines, Inc. (PBLS), 64.4%; Intellia Therapeutics, Inc. (NTLA), 35.4%; Adicet Bio, Inc. (ACET), 0.3%. The top 10 positions were 100.0% of the portfolio.
What did Regeneron Pharmaceuticals buy in Q2 2026?
Compared with Q1 2026, Regeneron Pharmaceuticals's largest estimated purchases were Parabilis Medicines, Inc. (PBLS) (new position, about $114.0 million). In total it opened 1 new positions and added to 0. Amounts are estimated from share-count changes at quarter-end prices.
When does Regeneron Pharmaceuticals file 13F reports?
Regeneron Pharmaceuticals's latest 13F-HR was filed August 7, 2026 and covers the quarter ended June 30, 2026. 13F-HR reports are due within 45 days of each quarter-end, so the Q3 2026 report is due by November 14, 2026.
What are the latest REGN SEC filings?
Regeneron Pharmaceuticals (REGN) filed its latest 10-K annual report on February 4, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on October 6, 2026 and a Form 4 insider filing on September 3, 2026.
What is REGN's SEC CIK number?
Regeneron Pharmaceuticals (REGN)'s SEC Central Index Key (CIK) is 872589. EDGAR lists every REGN filing under that number.
Ask anything about REGN
The research agent reads REGN's filings, financials, insider trades and 13F holders, then answers with sources.